Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Do you monitor for ILD on adjuvant T‑DXd the same way you do in metastatic patients—like in terms of how often you get imaging?
Related Questions
What potential challenges do you foresee in transitioning from current endocrine therapies to giredestrant, based on the lidERA trial results, in ER+, HER2- early breast cancer?
How do you modify your adjuvant therapy course in a patient experiencing liver dysfunction within the first few months of starting CDK4/6i?
Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
What are your top takeaways in Breast Cancer from ASCO 2025?
Considering the results of the I-SPY2 trial discussed at ASCO 2025, what would be your approach to treating a T1cN0 (tumor 1.5-1.9cm) young, fit patient? NACT THP x4 or surgery upfront?
In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
Would you add pertuzumab to adjuvant therapy for a premenopausal female with HR+, HER2+ IDC with N1mic disease?
